PRPedro Ruiz-Esteban

Pedro Ruiz-Esteban

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pedro Ruiz-Esteban has a total of 162 co-authors. Here are the top co-authors by number of shared publications:

  • Domingo Hernández

    Nephrology Department, Hospital Universitario de Canarias, Tenerife, Spain

    14 shared publications
  • Armando Torres

    University of La Laguna

    7 shared publications
  • Teresa Vazquez-Sanchez

    Nephrology Department, Hospital Universitario Regional de Málaga, Universidad de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA)-Plataforma BIONAND, RICORS2040 (RD21/0005/0012), E-29010 Malaga, Spain

    7 shared publications
  • Verónica López

    Department of Nephrology, Regional University Hospital of Málaga, University of Málaga, Málaga Biomedical Research Institute (IBIMA)–BIONAND Platform, RICORS2040 (RD21/0005/0012) and (RD24/0004/0026)

    7 shared publications
  • Myriam León

    Pathology Department, Hospital Universitario Regional de Málaga, Universidad de Málaga, Instituto de Investigación Biomédica de Málaga (IBIMA)-Plataforma BIONAND, RICORS2040 (RD21/0005/0012), E-29010 Málaga, Spain

    6 shared publications
  • D. Hernandez

    Nephrology Department, Carlos Haya University Hospital, Malaga and Torrecardenas Hospital, Almeria, Spain

    5 shared publications

Latest Publications

  • Open Access

    Impact of Systemic Inflammation on Ocular Surface Disease in Patients with Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis

    by Carmen Alba Linero, Patricia Gutiérrez, Julio Fontoba Diaz, Maria Victoria Girón Fernández, Pedro Ruiz-Esteban, Casilda Olveira

    Objective: To characterize the findings on the ocular surface of patients with cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (NCFB) and to correlate them with the degree of inflammation and systemic severity. Methods: This work is an observational, cross-sectional study of patients with CF and NCFB. A complete pulmonary evaluation (demographic and clinical data, spirometry, blood sample, computed tomography) and ophthalmological evaluation (visual acuity, biomicroscopy, OSDI test, TBUT test, Schirmer test, and InflammaDry test) were performed. Results: A total of 87 patients were recruited (CF=45, NCFB=42). Both the TBUT test (r=–0.373, p=0.001) and the Schirmer test (r=–0.280, p=0.010) correlated with the degree of systemic inflammation in our sample. Conclusion: Both CF and NCFB can cause a systemic inflammatory state related to altered ocular surface homeostasis, leading to evaporative and hyposecretory dry eye. However, in neither disease does this subclinical alteration translate into severe symptoms or serious ophthalmologic complications for these patients.

  • Dry eye disease and morphological changes in the anterior chamber in people with cystic fibrosis

    by Patricia Gutiérrez, Laura Jiménez, Jessica Martínez, Carmen Alba, María Victoria Girón, Gabriel Olveira, Pedro Ruiz-Esteban, Casilda Olveira


  • Open Access

    Rheumatoid arthritis and PLA2R‐associated mebranous nephropathy. Cause or coincidence?

    by Lara Perea‐Ortega, Ana Muñoz‐Sánchez, Myriam León‐Fradejas, Remedios Toledo Rojas, Pedro Ruiz‐Esteban, Verónica López‐Jiménez

    Key Clinical Message: The coexistence of rheumatoid arthritis (RA) and PLA2R‐associated membranous nephropathy (MN) is uncommon. It is difficult to demonstrate whether the mechanisms of renal pathology are triggered by RA, but it has been observed that the pro‐inflammatory molecules present in RA increase the expression of PLA2R. Rituximab could be effective in both conditions. RA affects 0.5% of adults in our country. It is an inflammatory disease that predominantly affects the joints causing destruction of the articular cartilage. Approximately 50% of patients present extra‐articular manifestations. Renal involvement is relatively frequent and clinically significant because it worsens the course and mortality of the primary disease. The histological renal damage observed in these patients includes a wide variety of entities and histological patterns with both glomerular and tubulointerstitial involvement, with secondary MN being one of the most frequent. Coexistence with primary MN is rare. We present the case of a 46‐year‐old male recently diagnosed with RA who was referred to the nephrology department for renal function deterioration and subnephrotic proteinuria. The autoimmune study showed positive anti‐PLA2R. Due to the unusual association between both entities, it was decided to perform a renal biopsy which showed abundant spikes. The immunofluorescence study showed contiguous parietal IgG positivity (3+). Immunohistochemistry showed positive granular IgG4, confirming the diagnosis of PLA2R‐associated MN. MN is one of the most common causes of nephrotic syndrome in adults. The determination of anti‐PLA2R has been a great advance in the rapid differential diagnosis of MN. In recent years, new target antigens associated with certain underlying pathologies have been discovered. However, PLA2R is not associated with any disease or exposure and therefore remains the antigen responsible for 80% of primary NMs. Anti‐PLA2R antibodies can be produced by loss of central or peripheral tolerance. Whether these mechanisms are triggered by RA itself is difficult to prove. The cytokine TNF‐like weak inducer of apoptosis (TWEAK) has been associated with RA. This proinflammatory molecule increases the expression of PLA2R in podocytes, sensitizing them to the damaging action of anti‐PLA2Rs, which could justify a causal relationship between the two pathologies. The anti‐PLA2R positivity in a patient with membranous nephropathy should not be sufficient to refrain from searching for a secondary cause, as a kidney biopsy is mandatory when another underlying disease coexists. Treatment should be tailored to the individual risk profile for progression. Rituximab could be an optimal option for both entities.


  • The effect of pulmonary rehabilitation on cardiovascular risk, oxidative stress and systemic inflammation in patients with COPD

    by Ana Muñoz Montiel, Pedro Ruiz-Esteban, Adolfo Doménech Del Río, Pedro Valdivielso, Miguel Ángel Sánchez Chaparro, Casilda Olveira


  • Open Access

    Differences in cardiovascular risk and health-related quality of life in COPD patients according to clinical phenotype

    by Ana Muñoz Montiel, Pedro Ruiz-Esteban, Adolfo Doménech Del Río, Pedro Valdivielso, Miguel Ángel Sánchez Chaparro, Casilda Olveira

    Chronic obstructive pulmonary disease (COPD) has a high prevalence and a major impact on health-related quality of life (HRQL). COPD exacerbations are an important cause of morbidity and mortality, affecting cardiovascular risk, and are associated with poorer health status. The aim of this study was to assess the association between cardiovascular risk (CVR) and HRQL, according to exacerbator or non-exacerbator phenotype. We undertook a cross-sectional, observational, descriptive study of 107 patients with COPD. Patients with two or more moderate exacerbations or one severe exacerbation in the previous year were considered as exacerbators. The CVR was calculated with the Framingham scale and SCORE (Systematic Coronary Risk Evaluation) and the HRQL was assessed with the generic questionnaire Short Form-36 Health Survey (SF-36), the St George Respiratory Questionnaire (SGRQ) and the COPD Assessment Test (CAT). Statistical analysis was done with SPSS version 26.0 for Windows. The SF-36 and the SGRQ showed lower values for the exacerbator phenotype, indicating a poorer quality of life. The CAT questionnaire showed values above 10 for the exacerbator phenotype, and lower values in the non-exacerbator group. After categorizing the sample according to their median age (65 years), we found a greater deterioration in HRQL in patients under 65 years of age according to the SF-36, the SGRQ and the CAT. We also detected differences in HRQL between non-exacerbator patients with a high CVR according to the Framingham (≥ 20%) and SCORE (≥ 5%) scales compared to those without this risk. A tendency towards worse HRQL was observed in non-exacerbator patients with a high CVR, which was statistically significant for the SGRQ impact domain on the SCORE scale. The CAT also showed a worse quality of life in non-exacerbator patients with a high CVR, which was significant in the Framingham model (Framingham high risk 8.41 vs non-high risk 6.05, p < 0.01). These differences were not observed in exacerbator patients. Our findings confirm that a high CVR influences HRQL in patients with COPD, especially in non-exacerbator patients with a high CVR, measured according to the SGRQ and the CAT.


  • Open Access

    Association between Cardiovascular Health, C-Reactive Protein, and Comorbidities in Spanish Urban-Dwelling Overweight/Obese Hypertensive Patients

    by Ana María Armas-Padrón, Miriam Sicilia-Sosvilla, Pedro Ruiz-Esteban, Armando Torres, Domingo Hernández

    The relationship between poorer cardiovascular health metrics (CVHM) plus low-grade inflammation (LGI) and hypertension-mediated organ damage (HMOD) and hypertension-related comorbidities (HRC) in hypertensive populations with an overweight/obese (Ow/Ob) hypertension-related phenotype is understudied. We examined the relationship between the CVHM score and the presence of LGI and Ow/Ob hypertension-associated phenotype morbidities and mortality in 243 hypertensive patients from an urban primary care center. We recorded the baseline CVHM score plus clinical data, including hs-C-reactive protein (CRP) and prevalent and incident HMOD-HRC and death. A total of 26 (10.7%) had a body mass index (BMI) < 25 kg/m2, 95 (31.1%) were overweight (BMI 25–29.9 kg/m2), and 122 (50.2%) were obese (BMI ≥ 30 kg/m2). There were 264 cases of HMOD-HRC and 9 deaths. Higher hs-CRP levels were observed as BMI increased. Linear regression analysis showed a significant correlation between BMI and hs-CRP, adjusted for confounders. Additionally, individuals with a higher hs-CRP tertile had a significant increase in BMI. Significantly lower log hs-CRP levels were found as the number of ideal CVHM scores rose. Multivariate binary logistic regression found the risk of HMOD-HRC increased significantly as the ideal CVHM scores decreased, and hs-CRP levels also correlated with HMOD-HRC in the whole cohort and in the Ow and Ob subpopulations. These findings highlight the need for early intervention targeting ideal CVHMs among hypertensive individuals with an Ow/Ob phenotype in order to attenuate the inflammatory state and prevent cardiovascular disease.


  • Open Access

    Time-Dependent Changes of Klotho and FGF-23 Levels after Kidney Transplantation: Role of Cold Ischemia Time, Renal Function and Graft Inflammation

    by Teresa Vazquez-Sanchez, Maria Dolores Sanchez-Niño, Pedro Ruiz-Esteban, Veronica López, Myriam León, Abelardo Caballero, Juan Francisco Ruiz-Escalera, Alberto Ortiz, Armando Torres, Mariano Rodriguez, et al.

    We investigated the evolution of serum klotho (s-Kl) and FGF-23 during the first two years post-kidney transplantation (KT), considering the cold ischemia time (CIT), glomerular filtration rate (GFR) and graft subclinical inflammation (SCI). We undertook a prospective, cohort, multicenter study of consecutive patients between April 2018 and January 2021 (with follow-up at 24 months). Subgroups were analyzed according to the median CIT (40 mL/min/1.73 m2) and the presence of SCI at month 3. A total of 147 patients were included. s-Kl and fibroblast growth factor-23 (FGF-23) levels were measured at baseline and at months 3, 12 and 24. Graft biopsies (n = 96) were performed at month 3. All patients had low s-Kl levels at month 3. Patients with CIT < 14 h exhibited a significant increase in s-Kl at month 24. In patients with CIT ≥ 14 h, s-Kl at month 3 fell and lower s-Kl levels were seen at month 24. Patients with a GFR > 40 had a lesser decrease in s-Kl at month 3. FGF-23 fell significantly at months 3 and 12 in both GFR groups, a reduction maintained during follow-up. There were significant inter-group differences in s-Kl from months 3 to 24. CIT, GFR at 3 months and SCI were significantly associated with s-KI at month 3. A reduction in s-Kl at month 3 post-KT could be explained by longer CIT and delayed graft function as well as by impaired graft function. Early SCI may regulate s-Kl increase post-KT.


  • Open Access

    Treatment of early borderline lesions in low immunological risk kidney transplant patients: a Spanish multicenter, randomized, controlled parallel-group study protocol: the TRAINING study

    by Domingo Hernández, Teresa Vázquez-Sánchez, Eugenia Sola, Veronica Lopez, Pedro Ruiz-Esteban, Abelardo Caballero, Eduardo Salido, Myriam Leon, Aurelio Rodriguez, Nuria Serra, et al.

    Background: Subclinical inflammation, including borderline lesions (BL), is very common (30–40%) after kidney transplantation (KT), even in low immunological risk patients, and can lead to interstitial fibrosis/tubular atrophy (IFTA) and worsening of renal function with graft loss. Few controlled studies have analyzed the therapeutic benefit of treating these BL on renal function and graft histology. Furthermore, these studies have only used bolus steroids, which may be insufficient to slow the progression of these lesions. Klotho, a transmembrane protein produced mainly in the kidney with antifibrotic properties, plays a crucial role in the senescence-inflammation binomial of kidney tissue. Systemic and local inflammation decrease renal tissue expression and soluble levels of α-klotho. It is therefore important to determine whether treatment of BL prevents a decrease in α-klotho levels, progression of IFTA, and loss of kidney function. Methods: The TRAINING study will randomize 80 patients with low immunological risk who will receive their first KT. The aim of the study is to determine whether the treatment of early BL (3rd month post-KT) with polyclonal rabbit antithymocyte globulin (Grafalon®) (6 mg/kg/day) prevents or decreases the progression of IFTA and the worsening of graft function compared to conventional therapy after two years post-KT, as well as to analyze whether treatment of BL with Grafalon® can modify the expression and levels of klotho, as well as the pro-inflammatory cytokines that regulate its expression. Discussion: This phase IV investigator-driven, randomized, placebo-controlled clinical trial will examine the efficacy and safety of Grafalon® treatment in low-immunological-risk KT patients with early BL. Trial registration: clinicaltrials.gov: NCT04936282. Registered June 23, 2021, https://clinicaltrials.gov/ct2/show/NCT04936282?term=NCT04936282&draw=2&rank=1. Protocol Version 2 of 21 January 2022. Sponsor: Canary Isles Institute for Health Research Foundation, Canary Isles (FIISC). mgomez@fciisc.org.


  • Open Access

    Abnormal ankle-brachial index, cardiovascular risk factors and healthy lifestyle factors in hypertensive patients: prospective cohort study from a primary care urban population

    by Ana María Armas-Padrón, Miriam Sicilia-Sosvilla, Sergio Rodríguez-Bello, María Dolores López-Carmona, Pedro Ruiz-Esteban, Domingo Hernández

    Background: Peripheral arterial disease (PAD) and arterial stiffness (AS) may be hypertension-mediated vascular lesions. Both are determined by an abnormal ankle-brachial index (ABI) and are predictors of cardiovascular disease (CVD) and mortality. We assessed the relationship in urban hypertensive patients between an abnormal ABI and an ideal cardiovascular health (CVH) score, plus other healthy factors, with unfavourable outcomes. Methods: We studied 243 hypertensive patients from a primary care urban population, followed for two years. Clinical data, comorbid conditions, including hypertension-mediated organ damage (HMOD) and hypertension-related comorbidities (HRC), hospitalizations and mortality were also recorded. Results: A low prevalence of ideal CVH was observed in urban hypertensive patients. The ABI ≤ 0.9 group (n = 16) showed a higher proportion of prior CVD other than PAD, mortality and hospitalizations than the ABI > 1.4 group (n = 41), and a poorer lipid, metabolic and renal profile. An inverse relationship between CVH score and ABI ≤ 0.9 and unfavourable outcomes (HMOD, HRC, death or hospitalization) was observed. Chronic kidney disease (CKD) and diabetes were independently associated with an ABI ≤ 0.9. Age, sex, diabetes, CKD, ABI ≤ 0.9 and ideal cholesterol were also associated with outcomes, but not other CVH metrics. Conclusions: Besides a low prevalence of ideal CVH, an inverse relationship between CVH score and ABI ≤ 0.9 and unfavourable outcomes was observed in hypertensive patients from an urban population. Stronger efforts to promote ideal CVH may improve outcomes in this particular population.


  • Open Access

    Cardio-renal benefits of sacubitril/valsartan in patients with advanced chronic kidney disease: experience in daily clinical practice

    by María Dolores Martínez-Esteban, Teresa Vázquez-Sánchez, Rafael Pozo-Álvarez, Alicia Moreno-Ortiz, Juana Alonso-Titos, Guillermo Martín-Reyes, Pedro Ruiz-Esteban, Daniel Gaitán-Román, Domingo Hernández

    Background: The association between cardiac complications, such as heart failure (HF), and chronic kidney disease (CKD) is well known. In this study, we examined the effectiveness and safety of treatment with neprilysin inhibition in patients with advanced chronic kidney disease (stage 3b-4). Methods: This single-centre, longitudinal, retrospective study of 31 months duration involved consecutive patients with CKD and HF with a reduced ejection fraction (HFrEF) who started treatment with sacubitril/valsartan. Glomerular filtration rate (GFR), cardiovascular risk factors, proteinuria, potassium, echocardiographic parameters and admissions for heart failure were analysed. Results: The study comprised 25 patients with a median age of 73.2 ± 5.9 years. The most frequent aetiology of heart failure was ischemic heart disease. The median GFR was 29.4 ± 8.3 ml/min/1.73 m2 and the left ventricular ejection fraction (LVEF) 36.4 ± 8.9%. The GFR improved after initiating the treatment (F = 3.396, p = 0.019), as did the LVEF at one year of follow-up (p = 0.018). The number of visits to the emergency department for heart failure was also reduced. No patients needed to start renal replacement therapy. Conclusions: This study shows that sacubitril/valsartan may play a beneficial role in patients who have advanced CKD and HFrEF, with a satisfactory safety profile.